Movement disorders in 2011: Translating new research findings into clinical practice

Nature Reviews Neurology

Volumn 8, Issue 2, 2012, Pages 65-66

  Klein, Christine ^a   Krainc, Dimitri ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; GLUTAMATE DECARBOXYLASE; PARVOVIRUS VECTOR;

CLINICAL PRACTICE; DISEASE COURSE; DISEASE MARKER; ENZYME ACTIVITY; GAUCHER DISEASE; GBA1 GENE; GENETIC ASSOCIATION; HUMAN; HUNTINGTON CHOREA; IMMUNOREACTIVITY; MOLECULAR PATHOLOGY; MUTATOR GENE; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; UNSPECIFIED SIDE EFFECT; VACUOLAR PROTEIN SORTING 35 GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ATTITUDE OF HEALTH PERSONNEL; BIOMEDICAL RESEARCH; EVIDENCE-BASED MEDICINE; HISTORY, 21ST CENTURY; HUMANS; MOVEMENT DISORDERS;

EID: 84857038919     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.212     Document Type: Review

References (9)

1. Dorsey, E. R. et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384-386 (2007). (Pubitemid 46184217)
2. Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 (2011).
3. Kiskinis, E. & Eggan, K. Progress toward the clinical application of patient-specific pluripotent stem cells. J. Clin. Invest. 120, 51-59 (2011).
4. Vilarino-Guell, C. et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89, 162-167 (2011).
5. Zimprich, A. et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168-175 (2011).
6. Kumar, K. W. et al. Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch. Neurol. (in press).
7. Lill, C. M. & Bertram, L. Complex genetics of neurodegenerative diseases. Semin. Neurol. (in press).
8. Yanamandra, K. et al. α-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS ONE 6, e18513 (2011).
9. LeWitt, P. A. et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309-319 (2011).